Paradoxical Sex-Specific Patterns of Autoantibodies Response to SARS-CoV-2 Infection

Yunxian Liu, PhD¹, Joseph E. Ebinger MD, MS¹, Rowann Mostafa, BS¹, Petra Budde, PhD⁵, Jana Gajewski, MSc⁵, Brian Walker, PhD¹, Sandy Joung, MHDS¹, Min Wu¹, Manuel Bräutigam, MSc⁵, Franziska Hespings, BSc^{5,6}, Elena Schäfer, MSc⁵, Ann-Sophie Schubert, MSc⁵, Hans-Dieter Zucht, PhD⁵, Jonathan Braun³, Gil Y. Melmed, MD, MS³, Kimia Sobhani, PhD⁴, Moshe Arditi^{1,6}, Jennifer E. Van Eyk, PhD^{1,2} Susan Cheng, MD, MPH^{1*} Justyna Fert-Bober, PhD^{1,2*}

*Equal contribution

From the ¹Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; ²Advanced Clinical Biosystems Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA; ³Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; ⁴Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA; ⁵Department of Medical Research, Oncimmune Germany GmbH, Dortmund, Germany; ⁶Ruhr University Bochum, TU Dortmund University, Germany; ⁶Department of Pediatrics, Division of Infectious Diseases and Immunology, Infectious and Immunologic Diseases Research Center (IIDRC), and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA

Correspondence. Justyna Fert-Bober, PhD, Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, phone (424) 315-2583, email Justyna.Fert-Bober@cshs.org; Susan Cheng, MD, MPH, Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, phone (310) 423-2726, email susan.cheng@cshs.org; Jennifer Van Eyk, PhD, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; phone: (310) , email Jennifer.VanEyk@cshs.org.

Word Count: 3,348 (main text)

Conflict of Interest: PB, JG, MB, FH, ES, ASS, and HDZ work for Oncimmune, a company that performed the serological assays on the biospecimens that were collected for this study. The remaining authors have no competing interests.

ABSTRACT

Background. Amidst the millions of individuals affected directly by the pandemic, pronounced sex differences in the susceptibility and response to SARS-CoV-2 infection remain poorly understood. Emerging evidence has highlighted the potential importance of autoimmune activation in modulating not only the acute response but also recovery trajectories following SARS-CoV-2 exposure. Given that immune-inflammatory activity can be sex-biased in the setting of severe COVID-19 illness, we deliberately examined sex-specific autoimmune reactivity to SARS-CoV-2 in the absence of extreme clinical disease.

Methods. We used a bead-based array containing over 90 autoantigens previously linked to a range of classic autoimmune diseases to assess autoantibody (AAB) titers in 177 participants. All participants had confirmed evidence of prior SARS-CoV-2 infection based on presence of positive anti-nucleocapsid IgG serology results (Abbott Diagnostics, Abbott Park, Illinois). We used multivariate analysis to determine whether sex-bias was associated with increased rates of AABs reactivity and symptom burden after SARS-CoV2 infection.

Results. 82.4% of AABs reactivity was associated with being male compared to 17.6% with female. We found a diversity of AABs responses that exhibited sex-specific patterns of frequency distribution as well as associations with symptomatology and symptom burden.

Conclusion. Our results reveal a remarkable sex-specific prevalence and selectivity of AAB responses to SARS-CoV-2. Further understanding of the nature of triggered and persistent AAB activation among men and women exposed to SARS-CoV-2 will be essential for developing effective interventions against immune-mediated sequelae of COVID-19.

KEYWORDS

SARS-CoV-2, COVID-19, AABs, Autoantigen selectivity, Sex differences.

INTRODUCTION

Mechanisms underlying sex differences in both susceptibility and response to SARS-CoV-2 infection remain poorly understood. Biological sex differences have become manifest with respect to vulnerability to infection, adaptive immune responses, and the equilibrium of inflammation and tissue repair in the resolution of infection (1). Recent evidence points to the possible contributions of triggering and persistence of autoimmune activation in SARS-CoV-2-infected COVID-19 patients (2, 3). Intriguingly, despite classic autoimmune diseases being more prevalent in females, emerging studies have revealed a paradoxical male predominance of autoimmune activation in the setting of severe COVID-19 illness (4). The extent to which such paradoxical sex differences in triggered autoimmunity may exist and persist across the broader clinical spectrum of SARS-CoV-2 infection is unclear. Recognizing that sex bias is potentially introduced when assessing autoimmune activation in the setting of more severe forms of COVID-19 illness, we deliberately aimed to interrogate sex-specific autoimmune activation after SARS-CoV-2 exposure in the absence of any extreme manifestations of clinical disease. Therefore, using an array to detect autoantibodies (AABs) to over 90 antigens previously linked to a range of classic autoimmune diseases, we sought to comprehensively examine the diversity of AAB responses in male and female health care workers (HCWs) who were exposed to SARS-CoV-2 and experienced even minimal or no symptoms.

RESULTS

Use of the multiplex assay resulted in complete AABs array profiling for all 177 plasma samples collected from our primary HCW participants, in addition to samples from the 53 healthy control and the 6 systemic lupus erythematosus (SLE) patient comparators. Demographic and clinical characteristics of the primary study sample are shown in **Table S2**. The primary cohort (N=177) had a mean age of 35 [IQR: 30-44] years including 65.0% women, 68.4% of non-white race, 28.2% of Hispanic/Latinx ethnicity, and 87% having reported at least mild symptoms associated with COVID-19.

Sex-Specific Frequency of Symptoms

As shown in **Figure 1**, the vast majority of symptoms related to prior COVID-19 infection were experienced similarly by men and women. Although specific symptoms appeared to be reported more frequently by men (e.g., chills, fever, shortness of breath, diarrhea, conjunctivitis) and other symptoms were reported more frequently by women (e.g., loss of appetite, nausea, and productive cough), these differences were not statistically significant (**Table S2**). Similar to the specific types of symptoms assessed, we observed that varying degrees of total symptom burden were also distributed relatively equally between the sexes (**Figure 1**).

Sex-Specific Frequency of AABs Response

In age-adjusted regression analyses, we examined the association of sex (female versus male) with measured plasma levels for each of the 91 autoantibodies assayed. Across the entire cohort, the majority of assayed AABs were associated with male sex and the minority with female sex but the sex-specific frequency and magnitudes of association varied by symptom burden (**Figure 2**). By comparison, a majority of the AABs assayed were significantly associated with SLE compared to healthy controls (HCs), with these associations predominantly seen in females compared to males (**Figure S1**). AABs were

also detected in HCs, with trend of AABs reactivity much more pronounce in male however, the AABs that showed reactivity in the HCs group were different compare to AABs reactive in SLE and HCWs individuals (**Figure 2**). In male among HCs AAB reactivity to colony stimulating factor 2 (CSF2), glycoprotein secreted by macrophages, Endothelin converting enzyme 1 (ECE1) and Dihydrolipoamide Branched Chain Transacylase E2 (DBT) involved in protein break down were the most dominated AABs. In female, among HCs reactivity to Transforming growth factor beta (TGFb) and Thyroid Peroxidase (TPO, marker for Hashimoto's disease or Graves' disease) showed the highest titer.

By contrast, among asymptomatic individuals, the breadth and magnitude of AAB reactivity was much more pronounced in females compared to males (**Figure 2B**). Notably, AABs to cytokine and chemokine antigens (IL6 and CSF2) involved in immune defense, together with lung specific proteins (gastrin release peptide (GRP) and serpin family B member 3 (SERPINB3), were predominantly elevated in asymptomatic females. By contrast, thyroid stimulating hormone receptor (TSHR) and lysine demethylase 6B (KDMA6B), which are known primary antigens in autoimmune diseases, were highly expressed in asymptomatic males.

Among all participants who had at least mild symptoms, the range and degree of AAB reactivity was more pronounced in males compared to females (**Figure 2C-D**). In participants with more than mild symptoms, 82.4% of AABs reactivity was associated with being male compared to 17.6% with female. The most abundant AABs in males including classical nuclear AABs such as small nuclear ribonucleoprotein polypeptide C (SNRPC) (SLE), nuclear mitotic apparatus protein 1 (NUMA1) (systemic sclerosis) and dihydrolipoamide S-succinyltransferase (DLST) (primary biliary cirrhosis). In this setting, the highest expressed antibody was Mov10 RISC complex RNA helicase (MOV10), which has been identified as an AAB that interacts with SARS-CoV-2 proteins (5).

Sex-Specific Associations of AABs Reactivity with Symptoms

In age-adjusted regression analyses we examined the sex-specific associations of distinct AABs levels with symptomatology (one symptom and marker per model), as shown in **Figures 3-4** and **Tables S3-S6**). In unadjusted regression analyses, 42 of 91 autoantibodies showed statistically significant reactivity that correspond to 18 distinct COVID-19 related symptoms for the whole cohort. In male, 63 out of 91 autoantibodies showed statistically significant reactivity corresponding to 18 distinct COVID-19 related symptoms. In unadjusted analysis in female, 41 out of 91 autoantibodies showed statistically significant reactivity corresponding to 14 COVID-19 related symptoms. After age-adjusted regression analyses, among males, 59 out of 63 AABs were associated with 18 out of all 18 symptoms that demonstrated significant associations. Among females, 38 out of 41 AABs demonstrated significant beta coefficients in relation to 13 out of 14 symptoms (**Figure 3**). Notably, in males, a large number of AABs had increased levels in relation to at least a mild overall symptoms burden while a substantial proportion of these same AABs exhibited lower levels in relation to asymptomatic status. By contrast, a smaller number of AABs exhibited generally consistently increased levels in relation to any level of overall symptom burden in females, including asymptomatic status.

In males, among the significantly associated AABs, small nuclear ribonucleoprotein polypeptides B (SNRPB), chromodomain helicase DNA binding protein 4 (CHD4) and chromogranin A (CHGA) were the most frequently associated with the distinct symptoms of productive cough and nasal congestion. In females, the AABs to dihydrolipoamide branched chain transacylase E2 (DBT) and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), were the most frequently elevated in relation to dry cough and loss of appetite (**Figure 3**). Overall profiles of AAB reactivity in relation to symptoms indicated the most frequent and significantly associated AABs in males appeared to follow an SLE-related pattern, whereas AAB profiles in females were more suggestive of poly-autoimmunity (6).

To further investigate the AAB sub-groups and select potential discriminatory symptoms, we applied hierarchical clustering analyses to identify similar magnitudes and directions of associations across AABs. The results of sex-specific two-dimensional clustering of symptoms variables in relation to AABs are shown in **Figure 4**. In males, the initially identified cluster included the symptoms of muscle aches and fatigue (cluster 1), with diarrhea and loss of appetite clustered next (cluster 2), and sneezing, runny nose, and nasal congestion also clustered together (cluster 3). In females, there were also three major clusters identified: dry cough, chills, and loss of appetite (cluster 1); sore throat, nausea, nasal congestion, and fever (cluster 2); and smell/taste change and shortness of breath (cluster 3). In males, clustering of AABs including C3 with TG antigens (cluster 1) and AABs to antigens representing LYZ and IFNA6 protein (cluster 2). In females, we found 5 clusters in total: ECE1 and HARS (cluster 1); SMD3, UBTF, and TOP1 (cluster 2); IL10 and S100A9 (cluster 3); HIST1H4A, MX1, and EXOSC10 (cluster 4); and, RPLP2 and TG (cluster 5).

DISCUSSION

In this study, comprehensive profiling of AAB activation in over 170 HCs with prior SARS-CoV-2 infection revealed several important sex-specific findings of interest. First, a surprisingly large number of the diverse autoantibodies assayed were differentially activated in males compared to females. Among previously infected individuals who were asymptomatic, the breadth of AABs response was more prominent in women than in men; by contrast, among previously infected individuals who experienced at least a mild burden of symptoms, the extent of antibody response was far more pronounced in men. Second, we found that the AABs response to symptom clusters were also sex-specific, with certain AABs-symptom associations seen more prominently in men compared to women, across the range of symptom burden. Finally, we observed these sex-specific AABs associations up to 6 months following symptomatology, indicating that SARS-CoV-2 triggers a complement of AABs responses that persists over time – in a sex-specific manner and irrespective of illness severity.

The current study expands from prior work in several ways. Extending from previously studies reporting on presence of post-COVID-19 autoimmunity,(3, 7) we employed a broad array of antibodies to over 90 distinct antigens previously linked to classic autoimmune conditions. Our results reveal a remarkable sex-specific prevalence and selectivity of the AABs response to SARS-CoV-2. Confirming and extending from the findings from prior reports, we found that a majority of our previously infected study participants had detectable circulating AABs against antigens such as ACE2, AQP4, C3, CHD4, CHGA, CXCL8, DBT, ECE1, ELANE, EXOSC10, HARS, HIST1H4A, IGF1R, INS, MOV10, MX1, PRTN3, RNF41, RPLP2, S100A9, SET, SNRPD1, SOX13, TG, TGFB1, TOP1, UBTF. Intriguingly, a distinct set of AABs to 59 antigens were highly correlated with reported symptoms in the male population, while another set of AABs to only 38 antigens were associated with symptoms in females. Notably, in males, we observed AABs associated with symptoms at a high

frequency (≥ 6 symptoms) as well as at a moderate frequency (≥ 4 symptoms). The high frequency associated AABs included SNRPB, a ribonucleoprotein that is widely prevalent in human SLE (8). The moderate frequency associated AABs included MOV10, CHGA, CHD4, HIST1H4A, ACE2, IFNA6, LYZ, RNF41. Importantly, both MOV10 and IFNA6 have been reported in patients infected with COVID-19 (5, 9). In females, we observed an overall lower frequency of significant symptoms associated AABs when compared to males. The 3 most prominent symptoms in females were associated with AABs to DBT and ROS1. Interestingly, AABs to DBT have been associated with lung cancer (10). Importantly, a number of AABs can be classified as implicated more frequently with systemic disease traits (i.e., multi-organ or multi-system) which may be particularly relevant to the more non-specific symptoms such as fatigue, fever, rashes, cold or allergy-type symptoms, weight loss, and muscular weakness. The sex specificity of triggered AABs reactivity in association with either distinct symptoms, or symptom clusters, may be related not only to sex differences in acute illness but also in post-acute and chronic clinical syndromes experienced by a substantial number of individuals recovering from COVID-19 (11).

While apparently paradoxical at the outset, our sex-specific findings are congruent with ongoing emerging data regarding potential mechanisms underlying sex differences in the susceptibility and response to SARS-CoV-2. Early studies reported that while men and women have similar prevalence, men with COVID-19 are at greater risk for worse outcomes and death independent of age (12, 13). Consistent with these findings, conventional inflammatory markers are found to be more substantially elevated in men compared to women who are hospitalized for COVID-19 (14). Accordingly, males in our study had a greater than 1.5-fold odds of AABs reactivity after adjusting for age. For classic autoimmune disease, clinical prevalence and incidence of autoimmune diseases tends to follow a male versus female pattern based on pathology. Male-predominant autoimmune diseases usually manifest clinically (i.e., show signs and symptoms of clinical disease) prior to age 50 and are characterized by acute inflammation and a Th1-type response, whereas autoimmune

diseases with a greater incidence in females that occur early in life have a clearer antibody-mediated pathology. Autoimmune diseases that have a greater incidence in females and also appear clinically later in life tend to present with evidence of chronic pathology, fibrosis, and increased numbers of autoantibodies are present (15).

The conventional sex bias seen for classic autoimmune diseases has been attributed in part to women who have a generally stronger cellular and humoral immunity, higher levels of circulating antibodies, more numerous circulating CD4+ T cells, and more robust cytokine production in response to immune stressors such as infection (16, 17). By contrast, males are now recognized as more vulnerable to the immune-modulated effects of active SARS-CoV-2 infection likely due to multiple mechanisms (e.g. lower immune cell expression of TLR7, lower observed antibody response, and lower interleukin mediated tissue resilience and tissue repair activity)(17) – and our results demonstrate the persistence of detectable downstream autoimmune sequelae. Importantly, our study also demonstrates for the first time a persistence of autoimmune activation in females compared to males following asymptomatic infection. As context, the stability of AABs in classic autoimmune diseases is known to vary substantially, with some autoantibodies fluctuating with flares of disease, while others remain stable.

We can speculate that the preponderance of AABs positivity in females – in the absence of symptomatic or recognized infection – represents initiation or proliferation and then persistence of self-reactive immunity with implications for post-acute chronic immune-driven disease states. These findings may be particularly relevant to rapidly accumulating evidence of the post-acute SARS-CoV-2 syndromes (e.g. “long-haul COVID”) that can emerge even weeks to months following resolution of mild or asymptomatic infection and with clinical manifestations that appear to differ in women compared to men (11).

The existence of autoantibodies within normal healthy individuals has been already shown by other investigators (18). The fact that across the breadth of AABs assayed in our healthy control sample, titers were also male predominant suggesting that larger population-based screening studies are needed to clarify our understanding of sex differences in basal AAB variation in the absence of clinical disease. Importantly, variations in the AAB titers found in the HCWs were different than those seen in healthy control subjects. In the latter group, the most dominant AAB was for granulocyte-macrophage colony-stimulating factor, also known as colony-stimulating factor 2 (CSF2), well-known to be a regulator of monocyte/macrophage differentiation. By contrast, AAB against CSF2 in the HCWs was barely reactive in the male population and were seen to be upregulated in female in asymptomatic group.

Several limitations of our study merit consideration. Our cohort includes HCWs from a single center who volunteered and responded to surveys, potentially limiting generalizability. We have a relatively small number of male subjects (n=63) that may have limited the ability to detect potential additional predictors of post-COVID autoimmunity; thus, further investigations of larger sized samples are needed. Although this was a prospective study, the survey method involved requesting participants to self-report symptoms occurring up to 6 months prior to the blood draw, contributing to potential recall bias. Whether examined subjectively or objectively, symptomatology can vary not only between but also within individuals over time. Similarly, the status of AAB reactivity may change over time and in relation to the timing of initial or repeated exposures. Thus, future longitudinal studies are warranted to understand temporal trends in similarly measured exposure and outcomes.

In summary, this comprehensive study of AABs to a wide array of antigens found that male sex carries the risk of diverse autoimmune activation following symptomatic COVID-19 illness, whereas female sex carries risk for a distinct profile of autoimmune activation following asymptomatic SARS-CoV-2 exposure. Importantly, both sets of sex-specific AAB

reactivity patterns were found to persist up to 6 months following associated symptomatology. Further understanding the nature of triggered and persistent AAB activation among individuals who are exposed to SARS-CoV-2 – and vulnerable to its potentially morbid clinical sequelae – will be essential for developing effective interventions and therapeutics.

METHODS

Study Sample. Our primary study cohort was derived from a diverse and unselected population of adults employed in a multisite healthcare delivery system located in Los Angeles County, including individuals with direct patient contact and others with non-patient-oriented work functions. All HCW participants provided detailed survey data on medical history, including prior COVID-19 exposures and infection in addition to COVID-19-related symptoms and exposures (19). For the current study, we included all participants (n=177) who had confirmed evidence of prior SARS-CoV-2 infection based on presence of positive anti-nucleocapsid IgG serology results (Abbott Diagnostics, Abbott Park, Illinois) (19). For all participants, EDTA plasma specimens were transported for assays within 1 hour of phlebotomy to the Cedars-Sinai Department of Pathology and Laboratory Medicine. Our secondary cohorts included healthy controls (n=53) who provided pre-pandemic serum samples obtained from the Bavarian Red Cross (Wiesentheid, Germany) with ethical approval from the Bayerische Landesärztekammer (Study No. 01/09). We also studied a classic autoimmune disease comparator cohort (n=6) of SLE patients who fulfilled the American College of Rheumatology (ACR) classification criteria for SLE (20) and had pre-pandemic serum samples collected by BioIVT (West Sussex, United Kingdom).

Autoantibody Assays. We utilized a panel of 91 protein antigens and cytokines in a multiplexed bead-based assay using Luminex FlexMAP 3D technology (21). The selected analytical targets can be grouped into different functional protein families or belong to immune-relevant biological pathways (22). Each antigen was covalently coupled to a distinct magnetic bead region (Luminex Corp, Austin, Texas) by carbodiimide. For each coupling reaction, up to 97 µg antigen and 4 × 10⁵ MagPlex™ beads per color were used (Table S1). Coupling efficiency was confirmed by incubation of 625 beads from each coupled region with a phycoerythrin-conjugated anti-6xHisTag antibody (Abcam, Cambridge, UK) at a concentration of 10 µg/mL for 45 min shaking at 900 rpm and room temperature.

Coupled beads were mixed to a final concentration of 62.5 beads/ μ L and stored in PBS supplemented with 1% bovine serum albumin, 0.1 % Tween 20 and 0.05% ProClin™ 300 (Merck KGaA, Darmstadt, Germany), at 4 °C until use (8). For analysis, serum or plasma samples were diluted 1:100 in assay buffer (50 % PBS with 1 % BSA, 50% LowCross-Buffer® (Candor Biosciences, Wangen, Germany), 1.3 μ g/ μ L E. coli lysate) and incubated for 20 min at room temperature. Next, the bead's mix (50 μ L) was added to each well of a 96-well plate and incubated with 50 μ L of diluted sample (1:100) in assay buffer for 22 h at 4–8°C in a plate shaker (900 rpm). Subsequently, after washing with PBS/0.1% Tween 20 the beads were incubated with R-phycoerythrin-labelled goat anti-human IgG detection antibody (Ab) (5 μ g/ml, Dianova, Hamburg, Germany) for 1 h at RT and washed again. The beads were analyzed in a FlexMap3D instrument (Luminex Corporation, Austin, Texas). The IgG reactivity values were given as median fluorescence intensity (MFI) and antigens fulfilling the minimum bead count criterion (>10 beads measured per bead ID) were exported for data analysis. In addition, triplicates of a COVID-19 positive reference sample (comprised of three HCWs) were run on each plate to calculate median intra-plate coefficient of variation (CV) and median inter-plate CV. The dynamic range was determined using blank samples and a control bead coupled to BSA (control_BSA) for the lower and hulgG (control_hulgGhi) for the upper MFI range. Log MFI of each AAB across all of our study samples (including 177 HCWs, 6 SLEs and 53 HCs) were standardized, by first subtracting the mean, and then dividing by the standard deviation.

Statistics. Parametric tests and non-parametric tests were used to compare normally distributed continuous variables and non-normally distributed or categorical variables, respectively. Histograms were used to display distribution of symptomatology as well as AABs reactivity against each antigen for the cohort in sex-pooled and sex-specific analyses. Ordinal logistic regression was used to examine the associations between AABs reactivity of each antigen and self-reported symptoms burden, defined as a symptom's severity score. The symptoms burden score was constructed based on the total number of reported

symptoms experienced within 6 months prior to the blood draw wherein a greater number of symptoms corresponded to a higher score (i.e., one point per symptom): we defined asymptomatic as represented by a score of 0, mild symptom burden as a score of 1 to 7, and more than mild symptom burden as a score of >7 . All statistical analyses were conducted using R (v3.5.1) and statistical significance was defined as a two-tailed P value <0.05 .

Study approval. All participants provided written informed consent and all protocols were approved by the Cedars-Sinai institutional review board.

AUTHOR CONTRIBUTION

JFB, JEVE, JB, KS and SC conceived and designed the overall CORALE study. JFB, JB, KS, JEVE, and SC acquired the CORALE data. PB, JG AND H-D Z conceived the AABS analysis of the study, and YL, MW, NS, PB, JG, JFB, KS, JEVE, SC, and MA analyzed the data. JFB, SC, and YL drafted the manuscript, and all authors edited the manuscript.

ACKNOWLEDGEMENTS

We are grateful to all the front-line HCWs in our healthcare system who continue to be dedicated to delivering the highest quality care for all patients. We would like to thank the following people for their collective effort: Koen Raedschelders, PhD, Danica-Mae Manalo, MS, James Stewart, PhD, John Prostko, MS, Edwin Frias, BS from Abbott.

DATA AVAILABILITY

Requests for de-identified data may be directed to the corresponding authors (JEVE, SC, JFB) and will be reviewed by the Office of Research Administration at Cedars-Sinai Medical Center prior to issuance of data sharing agreements. Data limitations are designed to ensure patient and participant confidentiality.

FUNDING

This work was supported in part by Cedars-Sinai Medical Center (JEE; SC), the Erika J Glazer Family Foundation (JEE; JEVE; SC), the F. Widjaja Family Foundation (JGB, GYM), the Helmsley Charitable Trust (JGB, GYM), and NIH grant K23-HL153888 (JEE).

REFERENCES

1. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, and Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nature Reviews Immunology*. 2020;20(7):442-7.
2. Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, and Fink SL. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). *Journal of translational autoimmunity*. 2020;3:100073.
3. Bhadelia N, Belkina AC, Olson A, Winters T, Urick P, Lin N, et al. Distinct Autoimmune Antibody Signatures Between Hospitalized Acute COVID-19 Patients, SARS-CoV-2 Convalescent Individuals, and Unexposed Pre-Pandemic Controls. *medRxiv*. 2021:2021.01.21.21249176.
4. Wehbe Z, Hammoud SH, Yassine HM, Fardoun M, El-Yazbi AF, and Eid AH. Molecular and Biological Mechanisms Underlying Gender Differences in COVID-19 Severity and Mortality. *Frontiers in immunology*. 2021;12:659339.
5. Wang JY, Zhang W, Roehrl MW, Roehrl VB, and Roehrl MH. An Autoantigen Profile of Human A549 Lung Cells Reveals Viral and Host Etiologic Molecular Attributes of Autoimmunity in COVID-19. *bioRxiv : the preprint server for biology*. 2021.
6. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, and Anaya J-M. Introducing Polyautoimmunity: Secondary Autoimmune Diseases No Longer Exist. *Autoimmune Diseases*. 2012;2012:254319.
7. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse Functional Autoantibodies in Patients with COVID-19. *Nature*. 2021.
8. Riemekasten G, and Hahn BH. Key autoantigens in SLE. *Rheumatology*. 2005;44(8):975-82.
9. Daamen AR, Bachali P, Owen KA, Kingsmore KM, Hubbard EL, Labonte AC, et al. Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. *Scientific Reports*. 2021;11(1):7052.

10. Moreno-Rubio J, Ponce S, Álvarez R, Olmedo ME, Falagan S, Mielgo X, et al. Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer. *Cancer Biol Med*. 2020;17(2):444-57.
11. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220-32.
12. Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Frontiers in Public Health*. 2020;8(152).
13. Ebinger JE, Achamallah N, Ji H, Claggett BL, Sun N, Botting P, et al. Pre-Existing Traits Associated with Covid-19 Illness Severity. *medRxiv*. 2020:2020.04.29.20084533.
14. Lau ES, McNeill JN, Paniagua SM, Liu EE, Wang JK, Bassett IV, et al. Sex differences in inflammatory markers in patients hospitalized with COVID-19 infection: Insights from the MGH COVID-19 patient registry. *PLoS One*. 2021;16(4):e0250774-e.
15. Fairweather D, Frisancho-Kiss S, and Rose NR. Sex differences in autoimmune disease from a pathological perspective. *Am J Pathol*. 2008;173(3):600-9.
16. Billi AC, Kahlenberg JM, and Gudjonsson JE. Sex bias in autoimmunity. *Current opinion in rheumatology*. 2019;31(1):53-61.
17. Bunders MJ, and Altfeld M. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. *Immunity*. 2020;53(3):487-95.
18. Al-Jabri AA, and Richens ER. Occurrence of autoantibodies in healthy Omani individuals. *J Sci Res Med Sci*. 2001;3(1):13-9.
19. Ebinger JE, Botwin GJ, Albert CM, Alotaibi M, Arditi M, Berg AH, et al. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study. *BMJ Open*. 2021;11(2):e043584.

20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis and rheumatism*. 1997;40(9):1725.
21. Günther A, Becker M, Göpfert J, Joos T, and Schneiderhan-Marra N. Comparison of Bead-Based Fluorescence Versus Planar Electrochemiluminescence Multiplex Immunoassays for Measuring Cytokines in Human Plasma. *Frontiers in immunology*. 2020;11:572634.
22. Budde P, Zucht HD, Vordenbäumen S, Goehler H, Fischer-Betz R, Gamer M, et al. Multiparametric detection of autoantibodies in systemic lupus erythematosus. *Lupus*. 2016;25(8):812-22.

FIGURE LEGENDS

Figure 1. Sex-specific frequency of symptoms type and overall symptoms burden, in men and women previously infected by SARS-CoV-2. In our primary study cohort, the distribution of experienced symptoms was generally similar between men and women (**Panel A**) with some exceptions including certain distinct symptoms being more frequent in men (e.g., chills, fever, conjunctivitis) and other distinct symptoms being more frequent in women (e.g., loss of appetite, nausea). In analyses of overall symptom burden, frequencies of asymptomatic, mildly symptomatic, and more than mildly symptomatic persons were relatively equally distributed between the sexes (**Panel B**).

Figure 2. Sex associations with AABs activation by symptoms burden, in men and women previously infected by SARS-CoV-2. The age-adjusted associations of sex (female versus male) with AABs activation across the panel of 91 antigens are shown for the primary cohort overall (**Panel A**) and within persons with varying loads of symptom burden: asymptomatic (**Panel B**), mild symptom burden (**Panel C**), more than mild symptom burden (**Panel D**).

Figure 3. Sex-specific associations of AABs reactivity with symptoms, in persons previously infected by SARS-CoV-2. From age-adjusted regression analyses, beta coefficients and negative log p values were obtained from examining the associations of symptoms with distinct autoantibodies. Associations for men are shown in **Panel A**. Associations for women are shown in **Panel B**.

Figure 4. Sex-specific clustering of symptoms and autoantibodies in men and women previously infected with SARS-CoV-2. Symptoms and autoantibodies were grouped based on similar directions and magnitudes of the beta coefficients from age-adjusted regression association analyses, with clusters selected based on a threshold of $h=0.5$ for

autoantibodies and $h=1.5$ for symptoms from Ward hierarchical clustering. Results are shown for men in **Panel A** and women in **Panel B**.

Figure 1.

A.

B.

Figure 3.

Figure 4.

A.

MEN

Symptoms Clusters

Cluster 1: muscle aches + fatigue

Cluster 2: diarrhea + loss of appetite

Cluster 3: sneezing + runny nose + nasal congestion

Autoantibody Clusters

Cluster 1: C3 + TG

Cluster 2: LYZ + IFNA6

B.

WOMEN

Symptoms Clusters

Cluster 1: cough dry + chills + loss of appetite

Cluster 2: sore throat + nausea + nasal congestion + fever

Cluster 3: smell taste + shortness of breath

Autoantibody Clusters

Cluster 1: ECE1 + HARS

Cluster 2: SMD3 + UBTF + TOP1

Cluster 3: IL10 + S100A9

Cluster 4: HIST1H4A + MX1 + EXOSC10

Cluster 5: RPLP2 + TG

SUPPLEMENTAL MATERIAL

Paradoxical Sex-Specific Patterns of AABs Response to SARS-CoV-2 Infection

Table S1. Composition of the AABs array.

No.	Protein Ref ID	Gene Symbol	Gene Name	Associated Traits
1	0105507583	NCL	Nucleolin (Protein C23)	R1ab protein homologue
2	0104741802	SRSF1	Serine/arginine-rich splicing factor 1	N-protein homologue
3	0104741211	RAE1	Ribonucleic acid export 1	ORF6 interaction partner
4	0104743520	EIF4H	Eukaryotic translation initiation factor 4H	NSP9 interaction partner
5	0105483772	MOV10	Mov10 RISC complex RNA helicase	N protein interaction partner
6	1043144426	NUMA1	Nuclear mitotic apparatus protein 1	pSS, CTD
7	0105510253	KDM6B	Lysine demethylase 6B	SLE, SSc
8	0105482537	ANXA2	Annexin A2	
9	0105488388	TLE1	Transducin-like enhancer of split 1	NSP13 interaction partner
10	1066861231	SOX13	Transcription factor SOX-13	PBC, type 1 diabetes
11	1066861238	SLC30A8	Solute carrier family 30 member 8	Type 1 diabetes
12	1066860558	SERPINB4	Serpin family B member 4	Lung-specific protein
13	1066858160	SERPINB3	Serpin family B member 3	Lung-specific protein
14	1066858257	IL4	Interleukin 4	Lung fibrosis
15	1066558274	SRP19	Signal recognition particle 19kDa	NSP8 interaction partner
16	0104741509	SET	Protein SET (HLA-DR-associated protein II)	R1a-Protein homologue
17	0105481639	GRP	Gastrin releasing peptide	Lung fibrosis
18	1105172472	AK4	Adenylate kinase 4, mitochondrial	Y14-Protein homologue
19	1066866713	HNRNPA2B1	Heterogeneous nuclear ribonucleoprotein A2/B1	RA, SLE
20	0104740269	LARP1	La ribonucleoprotein domain family, member 1	N protein interaction partner
21	1043139412	S100A9	S100 calcium binding protein A9	
22	0104745439	MIF	Macrophage migration inhibitory factor	
23	1047888619	UBTF	Upstream binding transcription factor, RNA polymerase I	CTD, SSc, SLE, SjS
24	1066838756	LTF	Lactotransferrin	Vasculitis
25	1066858459	S100A8	S100 calcium binding protein A8	
26	1066527806	PPL	Periplakin	Antigen for autoimmunity in idiopathic pulmonary fibrosis

27	1066559705	IL17A	Interleukin 17A	SLE, lung fibrosis
28	1066858740	IFNA4	Interferon alpha 4	SLE
29	0105489152	RNF41	E3 ubiquitin-protein ligase NRDP1 (RING finger protein 41)	NSP15 interaction partner
30	0105489248	VEGFA	Vascular endothelial growth factor A	
31	1066561916	HIST1H4A	Histone cluster 1 H4 family member a	Drug-induced lupus (DIL)
32	1066838464	ECE1	Endothelin converting enzyme 1	Biomarker pulmonary fibrosis
33	1066859699	ICA1	Islet cell autoantigen 1	Type 1 diabetes
34	0104744361	CHGA	Chromogranin A	
35	0105483201	NPM1	Nucleophosmin	SLE, SSc with pulmonary arterial hypertension
36	1066562106	CSF2	Colony stimulating factor 2	SLE, lung fibrosis
37	1066560001	CXCL8	C-X-C motif chemokine ligand 8	
38	1066859503	ELANE	Elastase, neutrophil expressed	Vasculitis
39	1043136644	IL6	Interleukin 6	SLE
40	1043140678	MX1	Interferon-induced GTP-binding protein Mx1	SLE, Chronic Pulmonary Diseases
41	1066562002	IL10	Interleukin 10	SLE, lung fibrosis
42	1066859715	CTSG	Cathepsin G	Vasculitis
43	1043140754	CHD3	Chromodomain helicase DNA binding protein 3	Myositis
44	1043144332	AQP4	Aquaporin 4	NMO
45	1066859023	LYZ	Lysozyme	Vasculitis
46	1066858547	IFNA6	Interferon alpha 6	SLE
47	1166361472	IGF1R	Insulin like growth factor 1 receptor	Autoimmune thyroiditis
48	1197785315	VIM	Vimentin	SLE, RA, CTD
49	1197682501	ROS1	ROS proto-oncogene 1, receptor tyrosine kinase	Lung-specific protein
50	1208494664	VEGFC	Vascular endothelial growth factor C	
51	1208494784	ENO1	Enolase 1	Vasculitis
52	0184571702	SRP54	Signal recognition particle 54	Myositis
53	0184571651	DBT	Dihydrolipoamide branched chain transacylase E2	Primary Biliary Cirrhosis (PBC)
54	0184571673	Chd4	Chromodomain helicase DNA binding protein 4	Myositis
55	0184649040	DLAT	Dihydrolipoamide S-acetyltransferase	Primary Biliary Cirrhosis (PBC)

56	0184571698	MDA5	Melanoma differentiation-associated protein 5	
57	0184571630	TRIM33	Tripartite motif containing 33	Myositis
58	0184571670	EXOSC10	Exosome component 10	Myositis/SSc
59	0184571689	SNRPB	Small nuclear ribonucleoprotein polypeptides B and B1	SLE
60	0184571639	SNRPC	Small nuclear ribonucleoprotein polypeptide C	SLE, CTD
61	0184571711	SNRNP70	Small nuclear ribonucleoprotein U1 subunit 70	SLE, CTD
62	0184571645	SSB	Sjogren syndrome antigen B	SSB / pSS, SLE
63	0184571685	SmD3	Small nuclear ribonucleoprotein D3	
64	0184571664	SNRPA	Small nuclear ribonucleoprotein polypeptide A	SLE, CTD
65	1058284508	TOP1	Topoisomerase (DNA) I	Diffuse SSc
66	0184571620	TROVE2	TROVE domain family member 2	SSA / SLE, SSB, CTD
67	0184571617	SNRPD1	Small nuclear ribonucleoprotein D1 polypeptide	SLE
68	0209387966	IFNA2	Interferon alpha-2	SLE/RA
69	0184648993	MPO	Myeloperoxidase	Vasculitis
70	0184649015	Sp100	SP100 nuclear antigen	Primary Biliary Cirrhosis (PBC)
71	0184649061	PRTN3	Proteinase 3	Vasculitis
72	1058284066	CENPB	Centromere protein B	Limited SSc
73	0201790353	TGFB1	Transforming growth factor beta 1	
74	0221992867	IFNW1	Interferon omega 1	SLE
75	0236191321	TPO	Thyroid peroxidase	Autoimmune thyroiditis
76	0348725826	PTPRN	Protein tyrosine phosphatase receptor type N	Type 1 diabetes
77	0348725809	TSHR	Thyroid stimulating hormone receptor	Autoimmune thyroiditis
78	1086925499	ACE2	Angiotensin I converting enzyme 2	
79	0184571695	HARS	Histidyl-tRNA synthetase	Anti-synthetase syndrome
80	0184649012	APOH	Apolipoprotein H	Anti-phospholipid syndrome (APS, SLE)
81	0184570981	RPLP2	Ribosomal protein lateral stalk subunit P2	SLE
82	0184571682	TRIM21	Tripartite motif containing 21	SSA / SLE, pSS, CTD
83	0201790340	SPP1	Secreted phosphoprotein 1	
84	1049727854	C3	Complement C1q B chain	SLE
85	0348725837	GAD65	Glutamate decarboxylase 2	

86	0348725819	TG	Thyroglobulin	Autoimmune thyroiditis
87	0365576846	INS	Insulin	Type 1 diabetes
88	0174988610	CTLA4	Cytotoxic T-lymphocyte associated protein 4	
89	0184649087	DLST	Dhydrolipoamide S-succinyltransferase	Primary Biliary Cirrhosis (PBC)
90	0105482432	NCOA6	Nuclear receptor coactivator 6	
91	Control_BSA		Control_BSA	
92	Control_Ecoli		Control_Ecoli	
93	Control_hulgGhi		Control_hulgGhi	
94	Control_hulgGlo		Control_hulgGlo	
95	Control_hulgM		Control_hulgM	
96	Control_hulgA		Control_hulgA	

Table S2. Demographic and clinical characteristics of 177 HCWs.

	Overall (N=177)	Women (N=115)	Men (N=62)	P value
Age (median [IQR])	35.00 [30.00, 44.00]	35.00 [30.00, 46.50]	34.50 [29.25, 40.75]	0.529
Race/Ethnicity (%)				
Hispanic/Latinx	50 (28.2)	34 (29.6)	16 (25.8)	0.531
Non-Hispanic Asian	46 (26.0)	30 (26.1)	16 (25.8)	
Non-Hispanic Black	15 (8.5)	11 (9.6)	4 (6.5)	
Non-Hispanic White	56 (31.6)	32 (27.8)	24 (38.7)	
Other	10 (5.6)	8 (7.0)	2 (3.2)	
Medical Conditions				
Cancer	2 (1.2)	2 (1.8)	0 (0.0)	0.797
Cardiovascular	2 (1.2)	1 (0.9)	1 (1.7)	1.000
Chronic Obstructive Pulmonary Disease	0 (0)	0 (0)	0 (0)	NA
Diabetes Mellitus	5 (2.9)	3 (2.7)	2 (3.3)	1.000
Hypertension	19 (11.0)	13 (11.4)	6 (10.2)	1.000
Immune	3 (1.7)	3 (2.7)	0 (0.0)	0.504
Prior diagnosis of COVID-19	68 (38.4)	42 (36.5)	26 (41.9)	0.586
Smoking	2 (1.1)	1 (0.9)	1 (1.6)	1.000
Vaping	14 (7.9)	6 (5.2)	8 (12.9)	0.130
Reported symptoms				
Chest pain	36 (20.3)	24 (20.9)	12 (19.4)	0.966
Chills	86 (48.6)	52 (45.2)	34 (54.8)	0.287
Conjunctivitis	11 (6.2)	5 (4.3)	6 (9.7)	0.282
Dry cough	100 (56.5)	64 (55.7)	36 (58.1)	0.881
Productive cough	44 (24.9)	32 (27.8)	12 (19.4)	0.288
Diarrhea	53 (29.9)	31 (27.0)	22 (35.5)	0.313
Fatigue	117 (66.1)	76 (66.1)	41 (66.1)	1.000
Fever	78 (44.1)	47 (40.9)	31 (50.0)	0.313
Headache	110 (62.1)	73 (63.5)	37 (59.7)	0.738
Loss of appetite	68 (38.4)	49 (42.6)	19 (30.6)	0.162
Muscle aches	101 (57.1)	66 (57.4)	35 (56.5)	1.000
Nasal congestion	93 (52.5)	60 (52.2)	33 (53.2)	1.000
Nausea	47 (26.6)	37 (32.2)	10 (16.1)	0.033
Runny nose	76 (42.9)	55 (47.8)	21 (33.9)	0.103
Shortness of breath	57 (32.2)	33 (28.7)	24 (38.7)	0.233

Skin changes	13 (7.3)	9 (7.8)	4 (6.5)	0.974
Smell and/or taste	92 (52.0)	61 (53.0)	31 (50.0)	0.819
Sneezing	83 (46.9)	56 (48.7)	27 (43.5)	0.619
Sore throat	71 (40.1)	48 (41.7)	23 (37.1)	0.660
Stroke symptoms	2 (1.1)	1 (0.9)	1 (1.6)	1.000
Vomiting	16 (9.0)	9 (7.8)	7 (11.3)	0.623
Symptom severity				0.982
Asymptomatic	23 (13.0)	15 (13%)	8 (12.9%)	
Mild symptom burden	64 (36.2)	41 (35.7%)	23 (37.1%)	
More than mild symptom burden	90 (50.8)	59 (51.3%)	31 (50%)	

Table S3. Associations of AABs reactivity with symptoms in men. Beta coefficients from age-adjusted regression analysis comparing males with a specific symptom burden to males without the same symptom are shown. Last three columns show beta coefficients from age-adjusted regression analysis comparing males with different levels of symptoms burdens to the pre-pandemic healthy control group.

Beta	Chest pain	Chills	Conjunctivitis	Cough productive	Diarrhea	Fatigue	Fever	Headache	Loss of appetite	Muscle aches	Nasal congestion	Nausea	Runny nose	Shortness of breath	Skin	Smell taste	Sneezing	Sore throat	Asymptomatic	Mild	More than mild
ACE2	0.467	0.202	0.164	0.602	0.461	0.232	0.091	0.161	0.258	0.486	0.738	0.015	0.634	0.536	-0.261	0.541	0.445	0.338	-0.428	0.362	0.470
AK4	0.117	0.133	-0.527	0.634	0.293	0.337	-0.016	0.187	0.224	0.201	0.411	0.132	0.207	0.183	-0.109	0.198	0.206	0.235	-0.372	-0.008	0.128
ANXA2	-0.168	-0.280	-0.101	0.604	0.250	0.126	-0.084	-0.114	0.390	-0.098	0.461	0.180	0.259	0.298	-0.256	0.403	0.325	0.203	0.138	0.385	0.431
APOH	0.483	0.095	0.528	0.579	0.153	-0.079	-0.014	-0.063	0.220	0.186	0.059	0.693	0.147	0.156	-0.002	-0.525	0.257	0.549	0.716	0.287	0.509
AQP4	-0.483	-0.382	-0.121	-0.448	-0.128	-0.425	-0.281	-0.419	-0.339	-0.189	-0.125	-0.725	-0.113	-0.626	-0.589	-0.468	-0.065	-0.405	0.509	0.590	-0.078
C3	0.094	0.119	0.503	0.505	0.420	0.386	0.107	-0.021	0.427	0.125	0.490	-0.444	0.361	0.367	-0.218	0.640	0.292	-0.002	-0.195	0.509	0.472
CADM3	-0.090	-0.168	-0.207	0.375	-0.300	-0.156	-0.046	-0.737	-0.144	0.160	0.334	-0.236	0.507	0.084	-0.276	0.090	0.179	0.008	0.596	0.709	0.622
CHD4	0.137	0.032	-0.221	0.882	0.228	0.147	-0.090	-0.127	0.370	0.003	0.627	0.009	0.452	0.109	-0.414	0.285	0.573	0.508	-0.228	0.406	0.415
CHGA	0.605	0.364	0.227	0.642	0.327	0.094	0.135	0.045	0.256	0.170	0.042	0.446	-0.132	0.584	0.453	0.163	0.276	0.578	-0.295	-0.422	0.085
CSF2	0.476	0.136	-0.155	0.654	0.591	0.176	0.047	0.245	0.198	0.471	0.518	0.342	0.430	0.365	-0.374	0.391	0.317	0.324	-0.652	0.212	0.338
CTLA4	-0.275	-0.174	0.257	0.428	0.198	0.215	-0.153	-0.231	0.195	0.017	0.682	-0.370	0.563	0.448	-0.244	0.710	0.420	-0.083	-0.148	0.688	0.473
CTSG	0.214	-0.043	-0.307	0.694	0.326	0.101	-0.056	0.085	0.159	0.289	0.723	0.102	0.684	0.322	-0.114	0.432	0.457	0.236	-0.248	0.307	0.496
CXCL8	0.287	0.100	-0.682	0.866	0.208	0.118	-0.094	0.110	0.254	0.377	0.589	0.204	0.522	0.311	-0.370	0.313	0.424	0.605	-0.429	-0.030	0.268
DBT	0.047	-0.285	-0.215	0.144	-0.245	-0.289	-0.157	-0.326	0.003	-0.391	0.262	0.253	0.570	-0.280	0.781	-0.314	0.125	-0.279	0.293	0.386	-0.100
DLAT	0.063	-0.107	0.174	0.190	0.290	0.094	-0.206	-0.114	0.002	0.108	0.262	-0.291	0.219	0.001	0.435	0.439	0.219	-0.054	0.295	0.286	0.405
ECE1	0.424	0.096	0.107	1.132	0.327	0.397	0.153	0.065	0.513	0.059	0.631	0.100	0.507	0.457	0.678	0.223	0.579	0.247	-0.610	-0.092	-0.078
EIF4H	0.069	0.067	-0.150	0.612	0.187	0.099	0.077	0.117	0.307	-0.156	0.421	-0.032	0.384	0.383	0.087	0.174	0.424	0.006	-0.142	0.492	0.434
ELANE	-0.177	-0.190	-0.473	0.319	0.115	0.258	-0.002	0.117	-0.162	0.273	0.606	-0.196	0.558	0.233	0.525	0.596	0.381	0.039	-0.061	0.325	0.645
EXOSC10	0.059	0.261	0.506	0.785	-0.111	0.176	-0.115	0.027	0.074	0.166	0.153	0.041	0.156	0.147	-0.349	0.367	0.244	0.324	-0.242	0.468	0.301
GRP	0.438	0.342	0.030	1.030	0.347	0.216	0.211	0.380	0.360	0.208	0.228	0.702	0.222	0.203	0.285	0.093	0.329	0.483	-0.532	0.156	-0.012
HARS	-0.059	0.149	0.350	0.620	0.273	0.393	-0.071	-0.074	0.260	0.155	0.500	-0.363	0.305	0.287	-0.247	0.497	0.326	0.178	-0.035	0.572	0.563
HIST1H4A	0.098	0.226	-0.329	0.874	0.167	0.288	-0.133	0.021	0.098	0.297	0.550	0.176	0.580	0.291	-0.379	0.312	0.316	0.479	-0.256	0.111	0.220
ICA1	0.006	-0.035	-0.713	0.863	0.182	0.297	0.018	0.229	0.130	0.200	0.387	0.363	0.017	0.406	-0.050	0.288	0.340	0.365	-0.161	0.037	0.455
IFNA4	-0.064	-0.035	0.465	0.476	0.282	0.381	0.007	-0.036	0.324	0.156	0.649	-0.321	0.597	0.285	0.316	0.624	0.464	-0.033	-0.300	0.533	0.481
IFNA6	0.274	0.144	0.375	0.650	0.211	0.336	-0.124	0.050	0.215	0.360	0.651	-0.002	0.723	0.328	-0.077	0.535	0.429	0.268	-0.633	0.120	0.178
IGF1R	-0.051	-0.094	0.285	0.294	0.449	0.212	-0.016	-0.029	0.206	0.225	0.517	-0.423	0.340	0.255	-0.292	0.649	0.188	-0.121	-0.269	0.449	0.403
IL17A	0.207	-0.128	-0.369	0.761	0.490	0.078	0.087	0.039	0.539	0.039	0.449	0.709	0.046	0.453	-0.249	0.077	0.378	0.262	0.043	-0.215	0.118
IL4	0.244	-0.077	-0.101	0.557	0.528	-0.075	-0.012	-0.317	0.460	0.261	0.659	0.048	0.532	0.294	-0.337	0.202	0.686	0.082	-0.233	0.263	0.380
IL6	0.251	-0.105	-0.038	0.573	-0.103	-0.200	0.079	-0.622	0.052	-0.338	0.455	0.318	0.256	0.223	-0.259	0.121	0.401	0.134	0.242	0.753	0.316
INS	-0.377	-0.319	-0.303	0.855	-0.308	-0.068	-0.292	-0.361	0.111	-0.210	0.246	-0.089	0.310	0.023	-0.165	-0.025	0.292	-0.126	0.582	0.800	0.434
LYZ	0.126	0.055	0.420	0.634	0.348	0.270	-0.017	0.079	0.229	0.345	0.823	-0.076	0.773	0.419	-0.020	0.554	0.573	0.173	-0.429	0.326	0.478
MDA5	0.233	0.005	-0.123	1.281	0.256	0.084	-0.190	0.070	0.298	0.020	0.578	0.479	0.437	0.232	0.431	0.319	0.412	0.676	-0.138	0.534	0.550
MIF	0.012	0.193	-0.210	0.957	0.103	0.256	0.008	-0.121	0.192	0.233	0.473	0.421	0.499	0.249	-0.066	0.252	0.476	0.690	0.271	0.682	0.826
MOV10	0.197	0.058	0.950	0.737	0.738	0.331	0.268	0.033	0.671	0.388	0.734	0.583	0.428	0.390	0.717	0.298	0.552	0.620	-0.338	0.497	0.678
MX1	0.096	0.003	-0.567	1.019	-0.109	-0.089	-0.036	-0.484	-0.010	0.005	0.615	-0.044	0.569	0.296	-0.452	0.406	0.449	0.214	0.299	0.648	0.678
NCL	0.057	0.204	-0.564	0.884	0.273	0.354	0.199	0.049	0.433	0.248	0.569	0.375	0.218	0.477	-0.445	0.278	0.277	0.561	-0.105	0.407	0.700
NPM1	-0.148	-0.256	0.074	0.750	0.099	0.265	-0.205	-0.238	0.174	0.129	0.407	-0.250	0.449	0.152	0.195	0.554	0.354	0.025	0.029	0.648	0.495
PRTN3	-0.084	-0.125	0.152	0.357	0.022	0.062	-0.054	-0.345	-0.045	0.167	0.493	0.092	0.432	0.222	-0.044	0.104	0.499	0.081	-0.198	0.320	0.263
RAE1	-0.226	-0.569	-0.854	0.209	0.352	-0.317	-0.250	-0.180	0.355	-0.187	0.403	0.354	0.446	-0.065	0.222	-0.167	0.363	-0.101	0.570	0.389	0.370
RNF41	0.017	0.063	-0.141	0.638	0.118	0.002	-0.011	-0.210	0.184	0.033	0.533	-0.079	0.545	0.304	-0.451	0.480	0.422	0.106	0.236	0.605	0.636
RPLP2	0.020	0.045	0.324	0.492	0.274	0.231	-0.037	-0.175	0.353	0.187	0.554	-0.052	0.523	0.413	-0.072	0.528	0.460	0.071	0.045	0.310	0.475
S100A9	-0.254	0.066	0.844	0.398	0.315	0.163	-0.027	-0.228	0.343	-0.005	0.560	-0.240	0.594	0.284	-0.308	0.581	0.474	-0.107	-0.064	0.607	0.491
SET	0.039	-0.140	0.480	0.380	0.053	0.186	-0.359	-0.327	0.169	-0.196	0.319	-0.309	0.436	0.153	-0.324	0.574	0.315	0.194	0.000	0.661	0.353
SLC30A8	-0.415	-0.038	0.434	-0.175	-0.016	0.400	0.140	0.112	0.113	0.340	0.661	-0.360	0.597	0.416	0.230	0.341	0.609	0.014	-0.073	0.369	0.434
SNRNP70	0.429	0.108	-0.260	1.066	0.556	0.069	-0.143	-0.053	0.424	0.222	0.414	0.005	0.502	0.511	-0.436	0.568	0.363	0.260	-0.189	0.140	0.487
SNRPA	0.564	0.025	-0.225	0.786	0.112	-0.397	0.039	-0.120	0.214	0.069	0.169	0.234	0.408	-0.181	0.040	-0.098	0.145	0.118	0.239	-0.188	-0.284
SNRPB	0.834	0.549	-0.389	1.357	0.171	0.325	-0.052	0.379	0.546	0.466	0.403	0.654	0.537	0.461	-0.725	0.538	0.424	0.733	-0.344	0.039	0.544
SNRPD1	-0.203	-0.019	-0.332	0.212	-0.270	-0.021	-0.525	0.085	-0.054	-0.333	0.168	0.051	0.415	0.061	-0.225	0.119	0.323	0.532	0.558	0.410	0.747
SOX13	0.255	0.108	-0.321	0.154	0.509	0.065	0.106	-0.056	0.182	-0.126	0.711	0.244	0.441	0.174	0.341	0.148	0.790	0.265	-0.057	0.172	0.698
SRP19	0.248	0.237	0.742	0.787	0.344	0.516	0.003	0.285	0.429	0.445	0.562	0.243	0.512	0.357	0.165	0.302	0.362	0.329	-0.145	0.281	0.593
SSB	0.247	0.007	-0.054	0.511	-0.151	-0.047	-0.374	0.010	0.013	0.098	0.043	0.117	0.125	-0.038	-0.275	0.097	0.312	0.583	0.073	0.474	0.601

TG	-0.112	0.141	0.527	0.353	0.343	0.391	0.005	-0.121	0.364	0.078	0.378	-0.496	0.242	0.249	-0.203	0.567	0.155	-0.113	-0.163	0.685	0.481
TGFB1	0.288	-0.365	-0.157	0.499	-0.087	-0.231	-0.403	-0.280	0.135	-0.222	0.041	-0.060	-0.102	0.247	-1.042	-0.160	0.189	0.092	0.812	0.867	0.520
TOP1	-0.008	0.382	-0.635	0.816	0.008	0.436	-0.013	0.024	0.125	0.407	0.289	0.151	0.178	0.197	-0.441	0.256	0.176	0.808	0.081	0.551	0.865
TRIM21	-0.049	0.611	0.395	0.158	0.080	0.507	0.169	0.215	0.102	0.603	0.365	0.242	0.462	-0.107	-0.692	0.225	0.210	0.283	-0.265	0.327	0.496
TROVE2	-0.118	0.179	0.734	0.446	0.276	0.404	-0.231	-0.015	0.249	0.152	0.357	-0.491	0.221	0.279	-0.381	0.631	0.128	-0.077	0.041	0.613	0.492
UBTF	0.051	0.143	-0.408	0.775	0.025	0.195	0.040	0.013	0.088	0.164	0.407	0.099	0.296	0.240	-0.124	0.303	0.355	0.409	0.011	0.464	0.769
VEGFA	-0.236	-0.063	-0.681	0.665	-0.091	0.162	-0.033	-0.232	0.197	0.157	0.554	-0.014	0.657	0.113	0.123	-0.035	0.365	0.259	0.519	0.754	0.824
VIM	-0.191	-0.380	-0.126	-0.090	0.337	0.123	-0.010	-0.102	-0.124	0.070	0.490	-0.234	0.150	0.029	-0.298	0.448	0.065	-0.229	-0.264	0.212	-0.022

Table S4. Associations of AABs reactivity with symptoms in men. P values from age-adjusted regression analysis comparing males with a specific symptom burden to males without the same symptom are shown. Last three columns show p values from age-adjusted regression analysis comparing males with different levels of symptoms burdens to the pre-pandemic healthy control group.

P value	Chest pain	Chills	Conjunctivitis	Cough productive	Diarrhea	Fatigue	Fever	Headache	Loss of appetite	Muscle aches	Nasal congestion	Nausea	Runny nose	Shortness of breath	Skin	Smell taste	Sneezing	Sore throat	Asymptomatic	Mild	More than mild
ACE2	0.154	0.462	0.719	0.068	0.088	0.399	0.737	0.559	0.360	0.061	0.004	0.966	0.023	0.043	0.623	0.036	0.096	0.208	0.222	0.140	0.137
AK4	0.677	0.573	0.173	0.024	0.208	0.148	0.946	0.426	0.352	0.370	0.064	0.664	0.395	0.424	0.811	0.377	0.371	0.307	0.431	0.980	0.699
ANXA2	0.574	0.260	0.808	0.043	0.313	0.613	0.730	0.648	0.125	0.681	0.050	0.577	0.316	0.220	0.594	0.086	0.182	0.405	0.731	0.122	0.129
APOH	0.151	0.738	0.256	0.089	0.586	0.779	0.960	0.823	0.448	0.492	0.827	0.055	0.616	0.573	0.998	0.048	0.352	0.044	0.036	0.153	0.068
AQP4	0.108	0.129	0.774	0.143	0.610	0.090	0.257	0.095	0.189	0.434	0.606	0.024	0.667	0.009	0.225	0.049	0.795	0.099	0.246	0.032	0.784
C3	0.794	0.692	0.310	0.164	0.157	0.197	0.717	0.945	0.163	0.663	0.085	0.251	0.244	0.209	0.707	0.022	0.321	0.994	0.503	0.032	0.150
CADM3	0.805	0.579	0.679	0.307	0.317	0.606	0.878	0.013	0.644	0.581	0.246	0.547	0.103	0.778	0.636	0.755	0.546	0.980	0.109	0.021	0.021
CHD4	0.656	0.902	0.602	0.003	0.369	0.566	0.720	0.619	0.156	0.990	0.008	0.978	0.085	0.664	0.400	0.241	0.020	0.039	0.494	0.124	0.085
CHGA	0.041	0.144	0.585	0.032	0.186	0.708	0.584	0.859	0.319	0.478	0.861	0.167	0.611	0.015	0.347	0.495	0.260	0.016	0.498	0.095	0.792
CSF2	0.120	0.598	0.716	0.034	0.018	0.495	0.852	0.340	0.453	0.053	0.033	0.304	0.104	0.143	0.451	0.108	0.208	0.197	0.182	0.500	0.314
CTL4	0.453	0.571	0.613	0.250	0.517	0.483	0.612	0.451	0.536	0.955	0.018	0.351	0.073	0.132	0.680	0.013	0.160	0.783	0.598	0.012	0.108
CTSG	0.524	0.879	0.508	0.038	0.239	0.719	0.839	0.762	0.581	0.280	0.005	0.779	0.016	0.237	0.833	0.103	0.093	0.389	0.511	0.234	0.112
CXCL8	0.373	0.710	0.123	0.007	0.437	0.663	0.721	0.685	0.357	0.140	0.020	0.558	0.059	0.236	0.475	0.222	0.106	0.019	0.325	0.921	0.388
DBT	0.871	0.240	0.594	0.627	0.311	0.234	0.510	0.179	0.992	0.090	0.259	0.422	0.021	0.238	0.093	0.173	0.601	0.240	0.515	0.163	0.734
DLAT	0.817	0.638	0.644	0.494	0.198	0.680	0.355	0.618	0.995	0.620	0.228	0.323	0.354	0.997	0.320	0.040	0.326	0.808	0.417	0.178	0.096
ECE1	0.180	0.718	0.808	<0.001	0.213	0.132	0.556	0.808	0.057	0.817	0.011	0.771	0.062	0.075	0.183	0.378	0.023	0.343	0.292	0.806	0.834
EIF4H	0.815	0.788	0.714	0.039	0.447	0.690	0.750	0.636	0.225	0.510	0.072	0.920	0.131	0.110	0.854	0.461	0.077	0.981	0.696	0.063	0.106
ELANE	0.615	0.518	0.330	0.372	0.693	0.380	0.993	0.691	0.592	0.331	0.029	0.607	0.064	0.418	0.353	0.031	0.184	0.893	0.858	0.185	0.046
EXOSC10	0.854	0.325	0.248	0.013	0.676	0.508	0.660	0.920	0.787	0.514	0.547	0.906	0.572	0.572	0.496	0.145	0.348	0.212	0.532	0.106	0.305
GRP	0.173	0.203	0.947	0.001	0.194	0.423	0.425	0.157	0.192	0.421	0.378	0.041	0.427	0.443	0.584	0.717	0.213	0.064	0.185	0.614	0.966
HARS	0.854	0.577	0.427	0.053	0.301	0.138	0.787	0.782	0.341	0.543	0.047	0.292	0.269	0.269	0.631	0.047	0.210	0.496	0.907	0.007	0.047
HIST1H4A	0.748	0.369	0.431	0.003	0.506	0.253	0.591	0.932	0.704	0.218	0.020	0.591	0.024	0.237	0.435	0.192	0.199	0.049	0.567	0.713	0.479
ICA1	0.986	0.899	0.117	0.009	0.510	0.283	0.947	0.409	0.648	0.453	0.143	0.311	0.954	0.132	0.926	0.276	0.210	0.178	0.677	0.898	0.122
IFNA4	0.845	0.899	0.303	0.150	0.298	0.161	0.978	0.896	0.246	0.552	0.011	0.364	0.032	0.285	0.548	0.014	0.081	0.901	0.346	0.023	0.107
IFNA6	0.399	0.597	0.403	0.045	0.432	0.213	0.641	0.853	0.440	0.162	0.010	0.994	0.008	0.214	0.883	0.035	0.103	0.312	0.147	0.666	0.591
IGF1R	0.881	0.739	0.544	0.394	0.108	0.454	0.955	0.918	0.479	0.407	0.053	0.247	0.245	0.357	0.593	0.014	0.499	0.664	0.440	0.107	0.201
IL17A	0.506	0.621	0.389	0.014	0.054	0.765	0.732	0.882	0.039	0.874	0.067	0.031	0.864	0.070	0.619	0.755	0.134	0.301	0.928	0.453	0.744
IL4	0.488	0.793	0.835	0.115	0.066	0.798	0.966	0.279	0.123	0.351	0.016	0.900	0.077	0.304	0.550	0.470	0.015	0.776	0.607	0.477	0.248
IL6	0.469	0.716	0.937	0.099	0.719	0.489	0.782	0.028	0.861	0.219	0.096	0.395	0.392	0.430	0.642	0.661	0.154	0.637	0.588	0.014	0.262
INS	0.224	0.218	0.482	0.005	0.232	0.795	0.252	0.163	0.679	0.399	0.323	0.792	0.250	0.929	0.742	0.918	0.251	0.620	0.040	0.001	0.072
LYZ	0.707	0.843	0.360	0.058	0.205	0.331	0.951	0.776	0.422	0.192	0.001	0.833	0.006	0.120	0.970	0.033	0.032	0.524	0.206	0.172	0.128
MDA5	0.444	0.983	0.771	<0.001	0.309	0.741	0.447	0.782	0.252	0.933	0.015	0.143	0.095	0.350	0.379	0.186	0.096	0.005	0.697	0.044	0.038
MIF	0.969	0.478	0.640	0.003	0.703	0.344	0.977	0.656	0.489	0.369	0.065	0.229	0.073	0.347	0.900	0.329	0.070	0.008	0.383	0.006	0.001
MOV10	0.613	0.859	0.073	0.058	0.019	0.306	0.397	0.918	0.040	0.208	0.015	0.161	0.200	0.216	0.249	0.333	0.079	0.047	0.330	0.113	0.039
MX1	0.788	0.993	0.245	0.003	0.712	0.763	0.902	0.099	0.973	0.987	0.027	0.910	0.061	0.306	0.428	0.148	0.119	0.461	0.391	0.016	0.020
NCL	0.856	0.437	0.190	0.004	0.292	0.174	0.439	0.853	0.104	0.320	0.020	0.266	0.421	0.059	0.377	0.265	0.279	0.026	0.805	0.126	0.015
NPM1	0.661	0.363	0.874	0.026	0.723	0.346	0.457	0.399	0.548	0.632	0.128	0.493	0.122	0.581	0.719	0.036	0.197	0.928	0.940	0.007	0.073
PRTN3	0.742	0.557	0.666	0.164	0.917	0.770	0.796	0.101	0.838	0.409	0.013	0.738	0.046	0.284	0.914	0.606	0.014	0.697	0.594	0.246	0.292
RAE1	0.466	0.025	0.043	0.507	0.169	0.220	0.325	0.488	0.180	0.450	0.101	0.290	0.094	0.798	0.658	0.500	0.151	0.690	0.197	0.206	0.230
RNF41	0.956	0.803	0.736	0.035	0.640	0.992	0.965	0.405	0.478	0.892	0.025	0.809	0.034	0.217	0.353	0.043	0.085	0.669	0.450	0.012	0.024
RPLP2	0.952	0.874	0.484	0.146	0.323	0.408	0.894	0.533	0.217	0.484	0.036	0.886	0.068	0.128	0.894	0.045	0.091	0.796	0.900	0.160	0.139
S100A9	0.448	0.813	0.065	0.241	0.255	0.560	0.923	0.416	0.231	0.984	0.034	0.508	0.037	0.298	0.567	0.027	0.081	0.696	0.847	0.009	0.093
SET	0.899	0.589	0.261	0.226	0.838	0.472	0.155	0.205	0.524	0.428	0.197	0.356	0.102	0.545	0.516	0.018	0.214	0.445	1.000	0.006	0.208
SLC30A8	0.169	0.880	0.298	0.569	0.950	0.111	0.573	0.659	0.664	0.158	0.005	0.270	0.020	0.089	0.637	0.154	0.012	0.954	0.831	0.176	0.117
SNRNP70	0.281	0.746	0.638	0.007	0.090	0.837	0.663	0.874	0.213	0.486	0.192	0.990	0.144	0.113	0.497	0.071	0.266	0.426	0.697	0.611	0.258
SNRPA	0.103	0.932	0.640	0.024	0.699	0.170	0.893	0.680	0.473	0.804	0.544	0.534	0.174	0.526	0.943	0.724	0.611	0.680	0.613	0.508	0.404
SNRNP	0.005	0.028	0.353	<0.001	0.498	0.198	0.833	0.133	0.033	0.051	0.093	0.043	0.038	0.060	0.135	0.023	0.085	0.002	0.383	0.877	0.110
SNRPD1	0.536	0.945	0.462	0.523	0.319	0.940	0.047	0.755	0.848	0.201	0.519	0.886	0.140	0.820	0.669	0.648	0.225	0.043	0.078	0.066	0.022
SOX13	0.399	0.670	0.443	0.616	0.040	0.797	0.669	0.826	0.483	0.603	0.002	0.456	0.089	0.481	0.484	0.539	0.001	0.283	0.888	0.540	0.020
SRP19	0.433	0.370	0.086	0.012	0.187	0.047	0.992	0.280	0.110	0.075	0.023	0.478	0.059	0.164	0.746	0.228	0.160	0.202	0.720	0.270	0.033
SSB	0.415	0.978	0.897	0.093	0.547	0.851	0.129	0.967	0.961	0.686	0.860	0.722	0.635	0.878	0.573	0.687	0.207	0.016	0.852	0.098	0.027

TG	0.747	0.625	0.267	0.313	0.229	0.172	0.985	0.675	0.216	0.777	0.168	0.181	0.417	0.376	0.715	0.036	0.585	0.688	0.607	0.006	0.127
TGFB1	0.381	0.181	0.730	0.132	0.751	0.400	0.131	0.307	0.633	0.398	0.876	0.867	0.720	0.356	0.045	0.541	0.483	0.733	0.051	0.008	0.056
TOP1	0.980	0.134	0.132	0.007	0.974	0.086	0.958	0.925	0.636	0.095	0.238	0.651	0.505	0.433	0.372	0.295	0.484	0.001	0.815	0.029	0.001
TRIM21	0.885	0.028	0.399	0.647	0.775	0.070	0.543	0.447	0.727	0.023	0.176	0.509	0.113	0.698	0.203	0.405	0.450	0.307	0.319	0.241	0.073
TROVE2	0.738	0.544	0.129	0.211	0.345	0.167	0.423	0.960	0.410	0.589	0.203	0.196	0.469	0.331	0.502	0.022	0.658	0.791	0.893	0.010	0.108
UBTF	0.847	0.517	0.261	0.003	0.908	0.376	0.852	0.954	0.696	0.436	0.050	0.730	0.192	0.262	0.770	0.146	0.097	0.055	0.979	0.059	0.005
VEGFA	0.459	0.813	0.119	0.037	0.731	0.543	0.901	0.382	0.470	0.537	0.027	0.968	0.015	0.665	0.811	0.890	0.160	0.319	0.108	0.008	0.001
VIM	0.524	0.125	0.761	0.768	0.172	0.622	0.967	0.683	0.630	0.769	0.037	0.469	0.564	0.906	0.536	0.057	0.790	0.348	0.539	0.529	0.942

Table S5. Associations of AABs reactivity with symptoms in women. Beta coefficients from age-adjusted regression analysis comparing males with a specific symptom burden to females without the same symptom are shown. Last three columns show beta coefficients from age-adjusted regression analysis comparing females with different levels of symptoms burdens to the pre-pandemic healthy control group.

Beta	Chest pain	Chills	Conjunctivitis	Cough dry	Fever	Loss of appetite	Nasal congestion	Nausea	Shortness of breath	Skin	Smell taste	Sore throat	Vomiting	Asymptomatic	Mild	More than mild
AQP4	-0.093	0.029	-0.029	-0.150	0.130	-0.174	-0.251	-0.262	-0.022	-0.252	-0.201	-0.465	0.207	0.479	0.499	-0.121
C3	-0.388	-0.248	-0.372	-0.130	0.091	-0.158	-0.138	-0.048	-0.064	0.162	0.177	-0.173	0.470	0.429	0.492	0.274
CENPB	-0.065	-0.169	-0.328	-0.239	0.036	-0.141	-0.046	0.069	0.161	0.004	0.204	-0.043	0.700	0.369	0.357	0.443
CHD3	-0.385	-0.438	0.019	-0.102	-0.260	-0.117	-0.266	-0.021	-0.007	0.796	0.124	-0.305	0.200	1.041	1.062	0.485
CHD4	0.054	-0.404	-0.691	-0.203	-0.116	-0.280	0.120	0.028	0.244	0.153	0.180	-0.156	-0.007	0.111	0.051	0.298
CHGA	0.052	-0.149	0.015	-0.003	0.096	-0.118	-0.349	-0.014	0.525	-0.471	-0.046	-0.187	0.062	0.215	0.007	0.068
DBT	-0.333	-0.448	-0.426	-0.400	-0.439	0.081	0.096	-0.038	0.001	0.033	0.032	0.055	-0.100	0.740	0.765	0.479
ECE1	0.069	-0.178	-0.044	-0.285	0.055	-0.252	0.082	0.054	0.240	-0.288	0.345	-0.125	0.737	0.689	0.478	0.313
ELANE	0.351	-0.113	1.044	-0.245	-0.166	-0.502	-0.094	0.140	0.167	-0.065	-0.104	-0.066	0.105	0.548	0.305	0.332
EXOSC10	-0.029	-0.222	-0.464	-0.429	-0.187	-0.471	-0.240	-0.031	0.108	0.078	-0.115	-0.150	0.195	0.992	0.372	0.396
GAD65	-0.246	-0.193	-0.248	-0.275	-0.098	-0.415	0.011	-0.157	0.090	-0.320	0.129	-0.162	-0.059	0.185	0.211	-0.113
HARS	-0.108	-0.215	0.042	-0.197	0.116	-0.059	-0.175	0.085	0.025	-0.313	0.223	-0.178	0.697	0.380	0.416	0.338
HIST1H4A	-0.071	-0.129	0.315	-0.399	-0.088	-0.267	-0.109	-0.019	0.257	0.083	0.052	-0.107	0.326	0.419	0.540	0.399
IFNA2	-0.404	-0.199	-0.556	-0.191	0.193	-0.103	-0.238	-0.046	0.058	-0.127	-0.156	0.138	0.632	0.421	0.376	0.042
IGF1R	-0.437	-0.124	-0.558	-0.097	0.031	-0.185	-0.218	-0.102	-0.207	-0.179	-0.120	-0.170	0.445	0.471	0.629	0.303
IL10	-0.230	-0.330	-0.160	-0.366	-0.155	-0.248	-0.124	-0.011	0.000	0.050	0.001	-0.217	0.247	0.760	0.277	0.293
INS	0.310	-0.112	1.450	-0.012	-0.211	-0.251	-0.079	-0.002	-0.172	-0.454	0.048	-0.062	0.238	0.442	0.510	0.428
MOV10	-0.150	0.022	1.161	-0.025	0.000	-0.024	-0.159	-0.128	-0.208	0.249	0.149	0.069	0.087	-0.195	-0.063	-0.161
MX1	0.076	-0.243	-0.525	-0.253	-0.227	-0.500	-0.139	-0.040	0.262	0.079	0.113	-0.104	0.183	0.741	0.524	0.468
PRTN3	0.273	-0.201	0.105	-0.144	0.000	-0.475	0.181	-0.227	0.285	0.987	-0.233	-0.340	-0.158	0.384	0.574	0.277
PTPRN	0.227	0.072	-0.083	-0.036	0.357	0.024	0.170	0.034	0.299	-0.221	0.311	0.053	0.086	-0.288	0.040	0.151
RNF41	-0.140	-0.129	-0.544	-0.233	0.031	-0.423	-0.091	-0.096	0.091	-0.250	0.121	-0.134	0.296	0.677	0.295	0.486
ROS1	-0.094	-0.051	-0.314	-0.214	-0.067	-0.371	-0.394	-0.124	-0.144	-0.318	-0.380	-0.262	0.172	0.395	0.203	0.036
RPLP2	-0.234	-0.243	-0.269	-0.264	0.048	-0.160	-0.249	-0.044	0.047	-0.221	0.060	-0.053	0.624	0.292	0.447	0.025
S100A8	-0.161	0.219	0.547	-0.077	0.383	0.189	-0.129	-0.176	0.142	-0.480	0.063	-0.028	0.289	0.504	0.178	0.472
S100A9	-0.355	-0.353	-0.214	-0.335	-0.149	-0.373	-0.286	-0.088	-0.004	-0.236	0.060	-0.298	0.309	1.036	0.544	0.356
SET	-0.046	-0.248	-0.482	-0.327	-0.121	-0.527	-0.043	-0.232	-0.029	0.224	-0.254	-0.214	0.424	0.553	0.303	0.038
SMD3	0.041	-0.288	-0.175	-0.417	-0.301	-0.269	-0.004	0.027	0.096	0.152	0.270	-0.005	0.259	0.325	0.316	0.287
SNRPC	0.124	-0.130	0.071	-0.075	0.148	-0.021	-0.049	0.393	-0.207	-0.196	-0.022	0.237	0.306	0.136	0.185	0.465
SOX13	0.088	-0.299	-0.182	-0.155	-0.018	-0.028	0.219	0.039	0.269	-0.701	-0.179	-0.034	-0.475	0.701	1.094	0.693
SP100	0.140	0.080	-0.023	-0.015	0.249	-0.102	-0.040	0.016	0.530	-0.203	-0.063	0.208	0.706	0.402	0.172	0.759
SRP54	-0.485	-0.188	0.225	-0.084	-0.076	0.120	-0.119	-0.140	-0.130	0.004	-0.005	0.011	-0.322	0.219	0.539	0.185
TG	-0.449	-0.256	-0.405	-0.144	0.104	-0.131	-0.251	0.015	-0.117	-0.182	0.151	-0.174	0.527	0.506	0.479	0.268
TGFB1	0.258	-0.142	-0.090	-0.298	-0.286	-0.250	-0.068	0.005	0.191	0.072	0.079	-0.382	0.190	-0.077	-0.218	-0.118
TOP1	-0.088	-0.200	-0.297	-0.476	-0.183	-0.390	-0.046	-0.001	0.111	0.094	0.179	-0.201	0.302	0.462	0.421	0.344
TPO	-0.410	-0.098	-0.621	-0.043	0.174	-0.063	-0.004	-0.434	0.072	0.148	0.036	-0.506	0.128	0.553	0.608	0.159
TRIM33	0.024	-0.233	0.267	-0.315	-0.104	-0.177	-0.018	0.098	0.100	0.201	0.004	-0.119	-0.086	-0.004	-0.025	-0.194
UBTF	-0.031	-0.221	-0.209	-0.503	-0.209	-0.228	-0.141	0.016	0.090	0.160	0.283	-0.211	0.281	0.580	0.394	0.126

Table S6. Associations of AABs reactivity with symptoms in women. P values from age-adjusted regression analysis comparing males with a specific symptom burden to females without the same symptom are shown. Last three columns show p values from age-adjusted regression analysis comparing females with different levels of symptoms burdens to the pre-pandemic healthy control group.

P value	Chest pain	Chills	Conjunctivitis	Cough dry	Fever	Loss of appetite	Nasal congestion	Nausea	Shortness of breath	Skin	Smell taste	Sore throat	Vomiting	Asymptomatic	Mild	More than mild
AQP4	0.690	0.879	0.951	0.429	0.502	0.363	0.183	0.193	0.918	0.473	0.289	0.014	0.556	0.260	0.154	0.668
C3	0.047	0.121	0.346	0.418	0.578	0.327	0.385	0.776	0.714	0.585	0.268	0.285	0.111	0.059	0.075	0.222
CENPB	0.773	0.353	0.466	0.189	0.845	0.444	0.800	0.721	0.421	0.991	0.260	0.814	0.036	0.132	0.200	0.096
CHD3	0.106	0.023	0.968	0.600	0.190	0.553	0.170	0.921	0.975	0.026	0.525	0.118	0.580	0.003	0.003	0.110
CHD4	0.822	0.038	0.152	0.299	0.562	0.156	0.539	0.893	0.256	0.675	0.357	0.430	0.984	0.751	0.882	0.340
CHGA	0.822	0.434	0.974	0.989	0.619	0.540	0.064	0.944	0.011	0.179	0.810	0.329	0.859	0.651	0.984	0.810
DBT	0.134	0.012	0.340	0.026	0.016	0.660	0.594	0.844	0.996	0.922	0.859	0.762	0.765	0.075	0.012	0.113
ECE1	0.739	0.294	0.916	0.090	0.750	0.139	0.629	0.763	0.196	0.358	0.039	0.466	0.017	0.016	0.111	0.184
ELANE	0.141	0.563	0.028	0.207	0.402	0.010	0.627	0.500	0.435	0.856	0.592	0.735	0.770	0.044	0.352	0.191
EXOSC10	0.906	0.266	0.347	0.030	0.359	0.018	0.227	0.883	0.624	0.834	0.563	0.458	0.598	0.002	0.255	0.184
GAD65	0.249	0.267	0.563	0.111	0.579	0.017	0.948	0.395	0.638	0.320	0.456	0.354	0.855	0.632	0.491	0.614
HARS	0.637	0.247	0.926	0.290	0.539	0.756	0.346	0.668	0.902	0.363	0.229	0.342	0.041	0.165	0.162	0.230
HIST1H4A	0.779	0.526	0.531	0.049	0.672	0.193	0.592	0.931	0.249	0.827	0.797	0.604	0.387	0.176	0.088	0.165
IFNA2	0.052	0.243	0.185	0.262	0.265	0.551	0.160	0.799	0.756	0.688	0.358	0.422	0.043	0.099	0.191	0.862
IGF1R	0.038	0.472	0.189	0.573	0.860	0.287	0.203	0.579	0.273	0.575	0.485	0.327	0.161	0.139	0.052	0.239
IL10	0.295	0.063	0.716	0.039	0.396	0.169	0.487	0.955	1.000	0.879	0.995	0.227	0.455	0.022	0.397	0.288
INS	0.221	0.587	0.004	0.954	0.315	0.228	0.702	0.993	0.449	0.234	0.817	0.765	0.533	0.179	0.155	0.123
MOV10	0.446	0.890	0.003	0.878	0.999	0.883	0.317	0.452	0.234	0.398	0.350	0.666	0.769	0.585	0.840	0.531
MX1	0.750	0.207	0.270	0.188	0.247	0.009	0.469	0.847	0.215	0.826	0.558	0.595	0.608	0.012	0.103	0.069
PRTN3	0.271	0.319	0.833	0.476	0.998	0.019	0.369	0.289	0.197	0.007	0.247	0.094	0.673	0.344	0.151	0.366
PTPRN	0.298	0.684	0.850	0.837	0.046	0.893	0.334	0.857	0.123	0.501	0.076	0.769	0.793	0.427	0.906	0.615
RNF41	0.569	0.518	0.270	0.243	0.878	0.035	0.650	0.651	0.680	0.499	0.544	0.508	0.424	0.034	0.356	0.069
ROS1	0.651	0.764	0.449	0.202	0.698	0.027	0.017	0.488	0.434	0.306	0.022	0.121	0.581	0.261	0.507	0.894
RPLP2	0.235	0.128	0.497	0.098	0.768	0.323	0.118	0.798	0.789	0.456	0.710	0.746	0.034	0.461	0.184	0.926
S100A8	0.475	0.232	0.226	0.677	0.039	0.309	0.483	0.368	0.482	0.157	0.731	0.881	0.395	0.226	0.579	0.116
S100A9	0.115	0.054	0.638	0.067	0.426	0.043	0.117	0.655	0.984	0.488	0.745	0.107	0.363	0.001	0.072	0.174
SET	0.839	0.177	0.289	0.073	0.518	0.004	0.813	0.236	0.885	0.511	0.165	0.248	0.212	0.178	0.378	0.896
SMD3	0.861	0.131	0.712	0.028	0.121	0.163	0.984	0.894	0.646	0.668	0.155	0.979	0.465	0.239	0.312	0.277
SNRPC	0.570	0.464	0.872	0.674	0.415	0.907	0.784	0.036	0.289	0.551	0.902	0.185	0.352	0.689	0.540	0.095
SOX13	0.693	0.098	0.685	0.392	0.923	0.879	0.224	0.840	0.175	0.035	0.321	0.851	0.155	0.072	0.001	0.014
SP100	0.572	0.692	0.964	0.943	0.226	0.618	0.843	0.939	0.016	0.586	0.756	0.307	0.057	0.103	0.532	0.016
SRP54	0.018	0.263	0.589	0.620	0.660	0.481	0.480	0.434	0.484	0.990	0.975	0.950	0.302	0.611	0.138	0.517
TG	0.031	0.131	0.336	0.398	0.550	0.446	0.138	0.936	0.531	0.564	0.375	0.312	0.093	0.040	0.097	0.274
TGFB1	0.231	0.419	0.835	0.088	0.107	0.156	0.698	0.979	0.320	0.825	0.651	0.029	0.559	0.849	0.574	0.689
TOP1	0.726	0.326	0.555	0.018	0.379	0.056	0.823	0.998	0.620	0.803	0.380	0.329	0.423	0.150	0.221	0.247
TPO	0.081	0.612	0.190	0.822	0.375	0.747	0.984	0.032	0.732	0.677	0.850	0.008	0.720	0.107	0.082	0.579
TRIM33	0.902	0.144	0.499	0.047	0.525	0.273	0.912	0.564	0.568	0.497	0.979	0.462	0.771	0.993	0.942	0.487
UBTF	0.908	0.303	0.692	0.018	0.337	0.292	0.509	0.944	0.703	0.686	0.185	0.328	0.478	0.057	0.295	0.654

Figure S1. Sex-specific associations of autoantibodies with SLE status. In age-

adjusted regression analyses, the breadth and magnitude of associations observed AABs reactivity and systemic lupus erythematosus (SLE) compared to health control status were predominantly seen in women compared to men. Beta coefficients were shown to the left, and negative log P values were shown to the right in each panel.